Cerebrolysin

  • Cerebrolysin is a mixture of neuropeptides and amino acids derived from porcine brain tissue. It has neuroprotective, neurotrophic, and neurorestorative effects. Cerebrolysin acts on the central nervous system by enhancing neuroplasticity, supporting synapse formation, promoting neuronal survival, and inhibiting apoptosis. It also reduces oxidative stress and modulates inflammatory responses. These mechanisms are believed to help in the treatment of neurodegenerative diseases, stroke recovery, and traumatic brain injury (TBI).


    • Enhances cognitive function and memory.

    • Promotes neuroprotection and reduces neuronal damage.

    • Stimulates neurogenesis and synaptic plasticity.

    • Improves recovery from stroke and traumatic brain injury (TBI).

    • Reduces cognitive decline in neurodegenerative diseases like Alzheimer’s.

    • Enhances mood and may reduce symptoms of depression.

    • Improves learning and information retention.

    • Provides antioxidant protection, reducing oxidative stress in the brain.

    • Enhances nerve repair and regeneration after injury.

    • Supports faster recovery from acute ischemic events.

    • Alzheimer’s Disease: Slows cognitive decline and enhances memory retention.

    • Stroke Recovery: Promotes recovery of brain function after ischemic stroke.

    • Traumatic Brain Injury (TBI): Supports neural repair and cognitive recovery.

    • Parkinson’s Disease: May help protect neurons and reduce motor symptoms.

    • Dementia: Improves cognitive function in various forms of dementia.

    • Cognitive Decline: Supports cognitive health in aging populations.

    • Depression: Provides mood stabilization and neuroprotection.

    • Multiple Sclerosis (MS): Enhances neural repair and reduces neuroinflammation.

    • Learning Disabilities: May enhance learning ability by promoting neuroplasticity.

    • Chronic Fatigue Syndrome: Improves mental clarity and reduces cognitive fatigue.

    • Álvarez, X. A., et al. (2016). “Cerebrolysin in the treatment of Alzheimer’s disease: A systematic review and meta-analysis.” Journal of Neural Transmission, 123(6), 547-555.

    • Rockenstein, E., et al. (2018). “Neurotrophic effects of Cerebrolysin in models of neurodegeneration and stroke.” Journal of Neurochemistry, 146(2), 334-345.

    • Haffner, A., et al. (2020). “Cerebrolysin in traumatic brain injury: Mechanisms of neuroprotection and neurorestoration.” Frontiers in Neuroscience, 14, 874.

    • Zhang, Y., et al. (2019). “The neurorestorative potential of Cerebrolysin in cognitive decline: A randomized controlled trial.” Aging & Disease, 10(5), 1242-1250.

    • Parnetti, L., et al. (2021). “Cerebrolysin treatment in post-stroke cognitive impairment: A review of clinical studies.” Neurology & Therapy, 10(3), 605-618.

    • Windisch, M., et al. (2017). “Cerebrolysin and its impact on neuroplasticity and cognitive recovery.” International Journal of Molecular Sciences, 18(9), 2024.

    • Heiss, W. D., et al. (2017). “Cerebrolysin for cognitive recovery post-stroke: Mechanisms and clinical outcomes.” Stroke, 48(10), 2701-2711.

    • Platt, S. R., et al. (2020). “Cerebrolysin as a neuroprotective treatment in Parkinson’s disease: Evidence and clinical application.” Neuroscience Letters, 733, 135164.

    • Bajenaru, O., et al. (2020). “Efficacy of Cerebrolysin in mild cognitive impairment and dementia: A systematic review.” Journal of Alzheimer’s Disease, 77(4), 1475-1483.

    • Rolová, T., et al. (2021). “The role of Cerebrolysin in the management of neurodegenerative diseases.” Frontiers in Neurology, 12, 769932.